CureVac (NASDAQ:CVAC) Shares Gap Up – Still a Buy?

CureVac (NASDAQ:CVAC)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $3.58, but opened at $3.83. CureVac shares last traded at $3.61, with a volume of 219,869 shares trading hands.

CureVac Stock Performance

The firm has a market cap of $792.54 million, a P/E ratio of 6.44 and a beta of 2.51. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company’s 50 day moving average is $3.56 and its 200 day moving average is $3.21.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CVAC. Private Advisor Group LLC purchased a new position in shares of CureVac in the third quarter worth about $30,000. International Assets Investment Management LLC bought a new stake in CureVac during the third quarter valued at approximately $35,000. Integrated Wealth Concepts LLC bought a new stake in shares of CureVac in the 3rd quarter worth approximately $35,000. Ballentine Partners LLC lifted its holdings in shares of CureVac by 58.6% in the 3rd quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock worth $67,000 after acquiring an additional 8,406 shares during the last quarter. Finally, Barclays PLC bought a new stake in shares of CureVac in the 3rd quarter worth approximately $67,000. 17.26% of the stock is owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.